Cost of noninfectious comorbidities in patients with HIV

Giovanni Guaraldi*, Stefano Zona, Marianna Menozzi, Federica Carli, Pietro Bagni, Alessandra Berti, Elisa Rossi, Gabriella Orlando, Giuliana Zoboli, Frank Palella

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Objectives: We hypothesized that the increased prevalence of noninfectious comorbidities (NICMs) observed among HIV-infected patients may result in increased direct costs of medical care compared to the general population. Our objective was to provide estimates of and describe factors contributing to direct costs for medical care among HIV-infected patients, focusing on NICM care expenditure. Methods: A case-control study analyzing direct medical care costs in 2009. Antiretroviral therapy (ART)-experienced HIV-infected patients (cases) were compared to age, sex, and race-matched adults from the general population, included in the CINECA ARNO database (controls). NICMs evaluated included cardiovascular disease, hypertension, diabetes mellitus, bone fractures, and renal failure. Medical care cost information evaluated included pharmacy, outpatient, and inpatient hospital expenditures. Linear regression models were constructed to evaluate predictors of total care cost for the controls and cases. Results: There were 2854 cases and 8562 controls. Mean age was 46 years and 37% were women. We analyzed data from 29,275 drug prescription records. Positive predictors of health care cost in the overall population: HIV infection (β = 2878; confdence interval (CI) = 2001-3755); polypathology (β = 8911; CI = 8356-9466); age (β = 62; CI = 45-79); and ART exposure (β = 18,773; CI = 17,873-19,672). Predictors of health care cost among cases: Center for Disease Control group C (β = 1548; CI = 330-2766); polypathology (β = 11,081; CI = 9447-12,716); age. 50 years (β = 1903; CI = 542-3264); protease inhibitor exposure (per month of use; β = 69; CI = 53-85); CD4 count, 200 cells/mm3 (β = 5438; CI = 3082-7795); and ART drug change (per change; β = 911; CI = 716-1106). Conclusion: Total cost of medical care is higher in cases than controls. Lower medical costs associated with higher CD4 strata are offset by increases in the care costs needed for advancing age, particularly for NICMs.

Original languageEnglish (US)
Pages (from-to)481-488
Number of pages8
JournalClinicoEconomics and Outcomes Research
Issue number1
StatePublished - Sep 20 2013


  • Antiretroviral therapy
  • HIV
  • Noninfectious comorbidities
  • Pharmacoeconomics

ASJC Scopus subject areas

  • Economics, Econometrics and Finance (miscellaneous)
  • Health Policy


Dive into the research topics of 'Cost of noninfectious comorbidities in patients with HIV'. Together they form a unique fingerprint.

Cite this